Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT01386957 Completed - Nephrotic Syndrome Clinical Trials

Steroid Treatment of Idiopathic Nephrotic Syndrome

Start date: July 2011
Phase:
Study type: Observational

Idiopathic nephrotic syndrome (INS) is the most frequent glomerular disease in childhood. Currently, all children with INS are treated at onset with steroids. The optimal duration and dosage of steroid therapy is debated. For each patient, the challenge is to minimise potential side effects of steroids, while achieving a good clinical response. The aim of our study is to assess the benefits and potential adverse effects of a prolonged initial corticosteroid regimen, for the treatment of the initial episode. The results will be compared with data obtained retrospectively. In addition genetic studies will be undertaken with the aim of evaluating pharmacodynamics of steroid treatment with the ultimate goal to individualise treatment in single patients. 1. Study group: children aged 6 months - 18 years, diagnosed with an initial episode of idiopathic nephrotic syndrome 2. Control group: data of children with a onset INS between January 2007 and December 2009 from the same area of the study group and treated with a short steroid regimen will be retrospectively analysed and compared

NCT ID: NCT01386944 Completed - Clinical trials for Restless Legs Syndrome

Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation

AURORA
Start date: July 2011
Phase:
Study type: Observational

The objective is to assess the effect of Neupro® on the severity of Restless Leg Syndrome (RLS) symptoms and augmentation in patients with augmentation associated with previous oral dopaminergic therapy. In addition, the change in treatment regimen used when switching to Neupro® will be evaluated.

NCT ID: NCT01384656 Completed - Clinical trials for Acute Coronary Syndrome

Effect of Glucose-insulin-potassium Solution on Myocardial Protection During Off-pump Coronary Bypass Surgery in Patients With Acute Coronary Syndrome

Start date: February 2011
Phase: Phase 4
Study type: Interventional

Patients undergoing multivessel off-pump coronary bypass surgery (OPCAB) inevitably experience cumulative ischemia-reperfusion injury at myocardium. Glucose-insulin-potassium (GIK) is a potentially useful adjunct to myocardial protection. This study was designed to evaluate the effects of GIK infusion on myocardium in patients undergoing OPCAB. Patients undergoing OPCAB with acute coronary syndrome are randomly assigned to GIK or Control group. The trial is double-blind and conducted at a single center.

NCT ID: NCT01384513 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Start date: August 4, 2011
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to compare the survival rates of patients with better risk disease undergoing hematopoietic stem cell transplant (HSCT) to the survival rates reported in the medical literature of similar patients undergoing reduced intensity HSCT from matched related donors.

NCT ID: NCT01382901 Completed - Clinical trials for Restless Legs Syndrome (RLS)

Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

Start date: March 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the safety of 2 dosage regimens of Intravenous (IV) iron Ferric Carboxymaltose (FCM) in comparison to placebo in patients with Restless Legs Syndrome (RLS)

NCT ID: NCT01382576 Completed - Clinical trials for Polycystic Ovary Syndrome

Women With Polycystic Ovary Syndrome Have Increased Plasma Chitotriosidase Activity

Start date: January 2010
Phase: N/A
Study type: Observational

In the present study, serum chitotriosidase activity and its relationship with insulin resistance were determined in patients with Polycystic Ovary Syndrome (PCOS).

NCT ID: NCT01382420 Recruiting - Cushing Syndrome Clinical Trials

Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma

Start date: May 2011
Phase: N/A
Study type: Interventional

Objective: To determine the metabolic effects of the adrenalectomy in subclinical Cushing's syndrome of adrenal incidentaloma. Methods: 234 subclinical cushing syndrome and adrenal incidentaloma will be randomly assigned into two groups(e.g adrenalectomy group and conservative treatment group).

NCT ID: NCT01382225 Completed - Dry Eye Syndrome Clinical Trials

Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome

Start date: July 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study was to determine if Sodium Hyaluronate, 0.18% is effective in treating the signs and symptoms of dry eye disease.

NCT ID: NCT01381809 Completed - Clinical trials for Myelodysplastic Syndromes

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

Start date: October 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that epoetin alfa works better than placebo in improving anemia in patients with lower-risk myelodysplastic syndromes (MDS). The safety of epoetin alfa will also be evaluated.

NCT ID: NCT01378546 No longer available - Clinical trials for Lambert Eaton Myasthenic Syndrome (LEMS)

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Start date: May 2005
Phase: N/A
Study type: Expanded Access

Lambert Eaton Myasthenic Syndrome (LEMS) is rare neurological disorder that results in muscle weakness and limited reflex activity. More than half of LEMS cases are associated with a malignancy, usually small cell lung cancer, and tend to progress more quickly than cases not coupled with malignant cells. 3,4diaminopyridine (3,4DAP)is a drug that has been demonstrated to be effective in treating the weakness associated with LEMS as it increases strength and improves autonomic symptoms in LEMS patients. It is not currently approved by the FDA for use in the United States. The investigators plan to use 3,4DAP to treat patients with LEMS here at the Columbia University MDA/ALS Research Center.